Al­ler­gan gets a win: FDA ap­proves ubro­gepant as cas­cade of treat­ments re­shape mi­graine field

Two weeks af­ter pub­lish­ing suc­cess­ful Phase III tri­al da­ta in the New Eng­land Jour­nal of Med­i­cine, Al­ler­gan has land­ed ap­proval for their new acute mi­graine pain drug ubro­gepant.

The drug, brand­ed Ubrelvy, is the lat­est in a se­ries of mi­graine drug ap­provals that have be­gun to re­shape an of­ten de­bil­i­tat­ing ail­ment the FDA es­ti­mates af­fects 37 mil­lion Amer­i­cans. It is al­so a sig­nif­i­cant win for Al­ler­gan, who has been rac­ing against Eli Lil­ly and Bio­haven to de­vel­op sim­i­lar pills to al­le­vi­ate mi­graine pain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER